Enzolytics Inc. (ENZC)
USD 0.0
(7.69%)
USD 0.0
(7.69%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.14 Million USD | 26.01% |
| 2022 | -2.9 Million USD | -105.85% |
| 2021 | -1.41 Million USD | 57.29% |
| 2020 | -3.3 Million USD | -398.72% |
| 2019 | -662.37 Thousand USD | 61.19% |
| 2018 | -1.7 Million USD | -109.16% |
| 2017 | -816.01 Thousand USD | -1174.22% |
| 2016 | -64.04 Thousand USD | 98.73% |
| 2015 | -5.04 Million USD | 0.0% |
| 2010 | -2.87 Million USD | -207.36% |
| 2009 | -935.41 Thousand USD | -135.44% |
| 2008 | -397.31 Thousand USD | -820.23% |
| 2007 | -43.17 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -172.72 Thousand USD | 0.0% |
| 2024 Q2 | 16.55 Thousand USD | 109.58% |
| 2023 Q3 | -2.25 Million USD | -80.47% |
| 2023 FY | -2.14 Million USD | 26.01% |
| 2023 Q1 | -418.3 Thousand USD | 55.39% |
| 2023 Q2 | -1.24 Million USD | -198.28% |
| 2022 Q2 | -772.8 Thousand USD | 6.66% |
| 2022 FY | -2.9 Million USD | -105.85% |
| 2022 Q4 | -937.76 Thousand USD | -158.07% |
| 2022 Q3 | -363.38 Thousand USD | 52.98% |
| 2022 Q1 | -827.92 Thousand USD | 0.0% |
| 2021 FY | -1.41 Million USD | 57.29% |
| 2021 Q1 | -564.34 Thousand USD | 38.59% |
| 2021 Q2 | -208.35 Thousand USD | 63.08% |
| 2021 Q3 | -379.41 Thousand USD | -82.1% |
| 2020 Q4 | -918.98 Thousand USD | 0.0% |
| 2020 FY | -3.3 Million USD | -398.72% |
| 2019 FY | -662.37 Thousand USD | 61.19% |
| 2018 FY | -1.7 Million USD | -109.16% |
| 2017 FY | -816.01 Thousand USD | -1174.22% |
| 2016 FY | -64.04 Thousand USD | 98.73% |
| 2015 FY | -5.04 Million USD | 0.0% |
| 2011 Q1 | -247.56 Thousand USD | 68.86% |
| 2011 Q2 | -214.02 Thousand USD | 13.54% |
| 2010 Q1 | -513.68 Thousand USD | 15.83% |
| 2010 FY | -2.87 Million USD | -207.36% |
| 2010 Q4 | -794.95 Thousand USD | -28.21% |
| 2010 Q3 | -620.02 Thousand USD | 34.49% |
| 2010 Q2 | -946.39 Thousand USD | -84.24% |
| 2009 Q3 | -191.23 Thousand USD | -135.74% |
| 2009 Q1 | -52.79 Thousand USD | 54.73% |
| 2009 Q2 | -81.12 Thousand USD | -53.66% |
| 2009 Q4 | -610.26 Thousand USD | -219.12% |
| 2009 FY | -935.41 Thousand USD | -135.44% |
| 2008 Q4 | -116.62 Thousand USD | 27.81% |
| 2008 Q2 | -18.1 Thousand USD | -2.84% |
| 2008 FY | -397.31 Thousand USD | -820.23% |
| 2008 Q3 | -161.54 Thousand USD | -792.5% |
| 2008 Q1 | -17.6 Thousand USD | 32.55% |
| 2007 Q3 | -1561.00 USD | 0.0% |
| 2007 FY | -43.17 Thousand USD | 0.0% |
| 2007 Q4 | -26.09 Thousand USD | -1571.68% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -60.907% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 57.403% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 87.96% |
| Nascent Biotech, Inc. | -2.22 Million USD | 3.636% |
| Rebus Holdings, Inc. | -664 Thousand USD | -223.614% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 102.625% |
| Qrons Inc. | -643.67 Thousand USD | -233.832% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -451.583% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 96.129% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -417.186% |
| Skye Bioscience, Inc. | -13.67 Million USD | 84.283% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 97.007% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 143.721% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -721.011% |
| SQZ Biotechnologies Company | -75.82 Million USD | 97.166% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 24.617% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -39.891% |
| Mesoblast Limited | -84.14 Million USD | 97.446% |
| Marizyme, Inc. | -34.08 Million USD | 93.696% |
| Genus plc | 6.4 Million USD | 133.575% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 122.056% |
| Pharming Group N.V. | -4.87 Million USD | 55.963% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -8.171% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -130.711% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 74.266% |
| ContraFect Corporation | -56.88 Million USD | 96.223% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 52.823% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -53.268% |
| IMV Inc. | -38.67 Million USD | 94.443% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 21.886% |
| MultiCell Technologies, Inc. | -722.81 USD | -297184.21% |
| ONE Bio Corp. | 13.68 Million USD | 115.706% |
| Accustem Sciences Inc. | -3.74 Million USD | 42.644% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 96.357% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -344.829% |
| Q BioMed Inc. | -3.44 Million USD | 37.637% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 160.701% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 18.22% |
| Biomind Labs Inc. | -1 Million USD | -112.836% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 96.091% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 25.935% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 67.678% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -15.256% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -7074.145% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 86.46% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -11.186% |
| GB Sciences, Inc. | -1.42 Million USD | -51.27% |
| Alpha Cognition Inc. | -9.7 Million USD | 77.86% |
| HST Global, Inc. | -140.9 Thousand USD | -1424.977% |
| CSL Limited | 3.7 Billion USD | 100.058% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -91.02% |
| Halberd Corporation | -75.05 Thousand USD | -2763.158% |
| Agentix Corp. | -1.37 Million USD | -56.646% |
| Resverlogix Corp. | -12.74 Million USD | 83.145% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 32.178% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.494% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -105.824% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 26.397% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -36.056% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 36.892% |
| AVAX Technologies, Inc. | 6.69 Million USD | 132.106% |
| Zenith Capital Corp. | -8.94 Million USD | 75.972% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.483% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -12234.539% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 12.484% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -1152.875% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -7.185% |
| Kadimastem Ltd | -3.04 Million USD | 29.322% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -118.362% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -71.083% |
| BioStem Technologies, Inc. | -7.77 Million USD | 72.377% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -1084.01% |
| LadRx Corporation | -3.82 Million USD | 43.802% |
| Cell Source, Inc. | -4.32 Million USD | 50.321% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -212.803% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -212.803% |
| NovAccess Global Inc. | -2.46 Million USD | 12.89% |
| Affymax, Inc. | -15.04 Million USD | 85.718% |
| Itoco Inc. | -919.14 Thousand USD | -133.784% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 49.302% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -92.029% |
| Mobile Lads Corp. | -554.55 Thousand USD | -287.485% |
| CytoDyn Inc. | -18.05 Million USD | 88.101% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -8437.147% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -876.381% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -280.505% |
| SYBLEU INC | -149.18 Thousand USD | -1340.408% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -18.305% |
| International Stem Cell Corporation | -663 Thousand USD | -224.103% |
| Bioxytran, Inc. | -3.82 Million USD | 43.751% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -3982.067% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -10464.405% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 94.075% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -32.806% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -192.022% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 30.929% |
| Neutra Corp. | -229.48 Thousand USD | -836.353% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 87.748% |
| PureTech Health plc | -146.19 Million USD | 98.53% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 90.001% |
| IXICO plc | -1.43 Million USD | -49.534% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 77.36% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 98.236% |
| CSL Limited | 3.81 Billion USD | 100.056% |
| Cellectis S.A. | -108.85 Million USD | 98.026% |